OBJECTIVE: The purpose of this study was to assess the effect of guanfacine extended release (GXR) adjunctive to a psychostimulant on oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). METHODS: A multicenter, double-blind, placebo-controlled dose-optimization study of GXR (1-4 mg/d) or placebo administered morning (a.m.) or evening (p.m.) adjunctive to psychostimulant was conducted in subjects ages 6-17 with suboptimal response to psychostimulant alone. Suboptimal response was defined as treatment with a stable dose of psychostimulant for ≥4 weeks with ADHD Rating Scale IV total score ≥24 and Clinical Global Impressions-Severity of Illness score ≥3, as well as investigator opinion. Primary efficacy and safety results have been reported previously. Secondary efficacy measures included the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L); these are reported herein. RESULTS: Significant reductions from baseline to the final on-treatment assessment on the oppositional subscale of the CPRS-R:L were seen with GXR plus psychostimulant compared with placebo plus psychostimulant, both in the overall study population (placebo-adjusted least squares [LS] mean change from baseline to the final on-treatment assessment: GXR a.m.+psychostimulant, -2.4, p=0.001; GXR p.m.+psychostimulant, -2.2, p=0.003) as well as in the subgroup of subjects with significant baseline oppositional symptoms (GXR a.m.+psychostimulant, -3.6, p=0.001; GXR p.m.+psychostimulant, -2.7, p=0.013). Treatment-emergent adverse events were reported by 77.3%, 76.3%, and 63.4% of subjects in the GXR a.m., GXR p.m., and placebo groups, respectively, in the overall study population. CONCLUSIONS:GXR adjunctive to a psychostimulant significantly reduced oppositional symptoms compared with placebo plus a psychostimulant in subjects with ADHD and a suboptimal response to psychostimulant alone.
RCT Entities:
OBJECTIVE: The purpose of this study was to assess the effect of guanfacine extended release (GXR) adjunctive to a psychostimulant on oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). METHODS: A multicenter, double-blind, placebo-controlled dose-optimization study of GXR (1-4 mg/d) or placebo administered morning (a.m.) or evening (p.m.) adjunctive to psychostimulant was conducted in subjects ages 6-17 with suboptimal response to psychostimulant alone. Suboptimal response was defined as treatment with a stable dose of psychostimulant for ≥4 weeks with ADHD Rating Scale IV total score ≥24 and Clinical Global Impressions-Severity of Illness score ≥3, as well as investigator opinion. Primary efficacy and safety results have been reported previously. Secondary efficacy measures included the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L); these are reported herein. RESULTS: Significant reductions from baseline to the final on-treatment assessment on the oppositional subscale of the CPRS-R:L were seen with GXR plus psychostimulant compared with placebo plus psychostimulant, both in the overall study population (placebo-adjusted least squares [LS] mean change from baseline to the final on-treatment assessment: GXR a.m.+psychostimulant, -2.4, p=0.001; GXR p.m.+psychostimulant, -2.2, p=0.003) as well as in the subgroup of subjects with significant baseline oppositional symptoms (GXR a.m.+psychostimulant, -3.6, p=0.001; GXR p.m.+psychostimulant, -2.7, p=0.013). Treatment-emergent adverse events were reported by 77.3%, 76.3%, and 63.4% of subjects in the GXR a.m., GXR p.m., and placebo groups, respectively, in the overall study population. CONCLUSIONS: GXR adjunctive to a psychostimulant significantly reduced oppositional symptoms compared with placebo plus a psychostimulant in subjects with ADHD and a suboptimal response to psychostimulant alone.
Authors: Thomas J Spencer; Howard B Abikoff; Daniel F Connor; Joseph Biederman; Steven R Pliszka; Samuel Boellner; Stephanie C Read; Raymond Pratt Journal: Clin Ther Date: 2006-03 Impact factor: 3.393
Authors: Gregory W van Wyk; Philip L Hazell; Michael R Kohn; Renee E Granger; Richard J Walton Journal: J Atten Disord Date: 2011-02-02 Impact factor: 3.256
Authors: Steven R Pliszka; M Lynn Crismon; Carroll W Hughes; C Keith Corners; Graham J Emslie; Peter S Jensen; James T McCRACKEN; James M Swanson; Molly Lopez Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-06 Impact factor: 8.829
Authors: S Kaplan; J Heiligenstein; S West; J Busner; D Harder; R Dittmann; C Casat; J F Wernicke Journal: J Atten Disord Date: 2004-10 Impact factor: 3.256
Authors: Joseph Biederman; Thomas J Spencer; Jeffrey H Newcorn; Haitao Gao; Denái R Milton; Peter D Feldman; Michael M Witte Journal: Psychopharmacology (Berl) Date: 2006-11-09 Impact factor: 4.530
Authors: Joseph Biederman; Raun D Melmed; Anil Patel; Keith McBurnett; Jennifer Konow; Andrew Lyne; Noreen Scherer Journal: Pediatrics Date: 2008-01 Impact factor: 7.124
Authors: Theresa Harpold; Joseph Biederman; Martin Gignac; Paul Hammerness; Craig Surman; Anya Potter; Eric Mick Journal: J Nerv Ment Dis Date: 2007-07 Impact factor: 2.254
Authors: Laura C Politte; Lawrence Scahill; Janet Figueroa; James T McCracken; Bryan King; Christopher J McDougle Journal: Neuropsychopharmacology Date: 2018-02-27 Impact factor: 7.853